Cardenilimab Combined With Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorLi Zhang
About this trial
The goal of this trial is to test the efficacy and safety of cardenilimab combined with chemotherapy in the conversion therapy of locally advanced unresectable esophageal squamous cell carcinoma.
type of study: clinical trial
Eligibility criteria
Qualifiers
Absolute neutrophil count (ANC) ≥1.5x109/L without using granulocyte colony-stimulating factor in the past 14 days;
Without blood transfusion in the past 14 days, platelets ≥100×109/L;
Hemoglobin >9g/dL without blood transfusion or erythropoietin use in the past 14 days;
Total bilirubin ≤1.5×upper limit of normal (ULN);
Disqualifiers
Other malignant diseases diagnosed within 5 years before the first dose (excluding radical basal cell carcinoma of the skin, squamous epithelial carcinoma of the skin, and/or carcinoma in situ that has been radically resected);
Endoscopically known signs of active bleeding in the lesion;
Currently participating in interventional clinical research treatment, or have received other research drugs or used research equipment within 4 weeks before the first dose;
Have previously received the following therapies: anti-PD-1, anti-PD-L1 or anti-PD-L2 drugs or another type of stimulating or synergistic inhibition of T cell receptors (including but not limited to CTLA-4, OX-40, CD137 etc.) drugs;
Trial design
Treatments tested in this trial
- Cardenilimab Combined With Chemotherapy
Treatment groups
43 Participants
are divided into 1 treatment groupSponsors and collaborators
Li Zhang
Lead sponsor
Tongji Hospital
Sponsor institution
Source ClinicalTrials.gov